NCT06523127 Withholding of Life-sustaining Treatment and Quality of Life After Severe Acute Brain Injury: Qualitative Analysis and Ethical Issues
| NCT ID | NCT06523127 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Quality of Life |
| Study Type | OBSERVATIONAL |
| Enrollment | 14 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2024-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 14 participants in total. It began in 2024-06-03 with a primary completion date of 2024-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Withdrawal of life-sustaining treatment affects 10-15% of ICU patients, including those with severe acute brain injury, whose care appears futile in terms of prognosis based on clinical and paraclinical data, expected quality of life, patient preferences, age, or reduced quality of life. There are few studies on withholding treatment compared with withdrawing treatment, and even fewer on survivors after a decision to withhold treatment. Quality of life is defined by WHO as "an individual's perception of his or her position in life in the context of the culture and value systems in which he or she lives and in relation to his or her goals, expectations, standards and concerns". The relationship between quality of life and neurological outcome after severe acute brain injury is controversial and therefore difficult to predict. That's why the investigators question the legitimacy of making decisions to withhold treatment from patients with severe acute brain injury based on their expected quality of life, when this prediction is uncertain.
Eligibility Criteria
Inclusion Criteria: Patients: * with severe acute brain injury (TBI, stroke, central nervous system infection). * admitted in the neurocritical care unit in 2022. * followed up 24 months after ICU between 15th April 2024 and 31st August 2024. Exclusion Criteria: Patients: * death in 2024, * refusal by patient or relative.
Contact & Investigator
Marie DAKENG, resident
PRINCIPAL INVESTIGATOR
Centre Hospitalier Universitaire de Saint Etienne
Frequently Asked Questions
Who can join the NCT06523127 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Quality of Life. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06523127 currently recruiting?
Yes, NCT06523127 is actively recruiting participants. Contact the research team at mcgperret@gmail.com for enrollment information.
Where is the NCT06523127 trial being conducted?
This trial is being conducted at Saint-Etienne, France.
Who is sponsoring the NCT06523127 clinical trial?
NCT06523127 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is Marie DAKENG, resident at Centre Hospitalier Universitaire de Saint Etienne. The trial plans to enroll 14 participants.